Phase 1 Brain Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed (confirmed by lab testing of tissue or cells) with a recurring brain tumour called an astrocytic tumour — including GBM (grades 2–4, IDH-wildtype), Astrocytoma (grades 2–4, IDH-mutant), or Diffuse midline glioma (including certain tumour types with specific gene mutations).
• People whose tumour measures 6 cm or less at its widest point — and if the tumour was recently removed, some measurable disease must still be visible on scans.
• People who have had at least a 6-month break since their last radiation therapy treatment.
• People who previously received a standard radiation dose (around 59.4–60 Gy in standard fractions, or lower) for their glioma.
• People who received a non-standard radiation dose or stereotactic radiosurgery may still be considered if there is a new tumour outside the original radiation area, or if biopsy or imaging confirms the tumour has truly progressed (confirm with trial site).
• People aged 18 years or older.
• People who are reasonably functional in daily life, as measured by standard medical scoring tools (ECOG score of 2 or lower, or Karnofsky score of 60% or higher).
• People whose blood test results meet specific thresholds for white blood cells, haemoglobin, platelets, liver function, and kidney function (confirm with trial site for exact values).
• People living with HIV who are on effective treatment and have had an undetectable viral load within the past 6 months.
• People with a history of hepatitis B who are on suppressive therapy with an undetectable viral load.
• People with a history of hepatitis C who have been successfully treated and cured, or who are currently on treatment with an undetectable viral load.
• People who have had or currently have another cancer, provided that cancer or its treatment is unlikely to interfere with this trial's safety or results.
• People with a history of heart disease or treatment with heart-affecting medicines, provided a doctor's assessment places their heart function at Class II or better on a standard heart health scale.
• People who are able to swallow whole capsules.
• People who are able to have MRI scans with contrast dye — or, if a person has a device incompatible with MRI, CT scans of sufficient quality may be accepted (confirm with trial site).
• People of child-bearing potential who agree to use adequate contraception before, during, and for 12 months after the trial, and who have a negative pregnancy test within 2 weeks of registering.
• People who are able to understand the trial and are willing to sign a written consent form — a legally authorised representative may do this on a participant's behalf.

Who may not be able to join:

• People who have not yet recovered from side effects of a previous cancer treatment (side effects still rated above grade 1), except for hair loss.
• People who are currently taking part in another clinical trial involving an investigational treatment.
• People who are currently taking medicines known to cause a blood condition called methemoglobinemia — examples include certain antibiotics (sulfonamides), nitrofurans, some anti-malarial drugs (primaquine, chloroquine), cyclophosphamide, or ifosfamide.
• People who have had a serious allergic reaction to a drug with a similar chemical or biological makeup to the trial drug, triapine.
• People with a known deficiency of an enzyme called G6PD (note: testing for this is not required to join).
• People with serious uncontrolled illness, active infections, or other significant health conditions that would make participation unsafe.
• People who are pregnant, as the trial drug and radiation carry potential risks to a developing baby.
• People who are breastfeeding, as the trial drug may pose a risk to nursing infants.

Important: Always verify eligibility with the trial site directly before applying.